AzTrials
AzTrials

Procedural Sedation and AnalgesiaNCT01126957

Combined Ketamine/Propofol for Emergency Department Procedural Sedation

A study testing Ketamine, Fentanyl and Propofol in people with Procedural Sedation and Analgesia, run by University of Missouri-Columbia at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record

Search all trials

Trial summary

Introduction Numerous drugs and combinations of drugs are used for procedural sedation and analgesia (PSA) in Emergency Departments, including propofol, ketamine, benzodiazepines, narcotics, barbiturates, and others, but propofol has gained popularity despite its potential to cause cardiac and respiratory depression. Read more about this study

Who is it for?
Ages 1 year and olderHealthy volunteers can take part
Conditions the study is for
Procedural Sedation and Analgesia
What is being tested?
Ketamine, Fentanyl and Propofol
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
107 participants
Where
1 siteUnited States
Study dates
May 2007to Mar 2010
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 year and older
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • Healthy individuals from 1 year of age and up without the below exclusion criteria

Who cannot join

  • Subjects: All patients who require ED conscious sedation and do not meet any of the following exclusion criteria are eligible for study participation:
  • Age < 1yr
  • History of prior adverse reaction to anesthesia
  • History of cardiac disease
  • History of pulmonary disease
  • Hepatic dysfunction
Show all 15Show fewer
  • Thyroid disease
  • Pregnancy
  • Porphyria
  • Psychiatric Illness
  • Allergy to eggs, soybeans, or sulfites
  • Increased intracranial or intraocular pressure
  • Active upper respiratory infection in children
  • Abnormal airway
  • ASA score of III or greater

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Missouri - Columbia dept. of Emergency Medicine

    Columbia, Missouri, 65212

Other trials in United States

About this study

Introduction

Numerous drugs and combinations of drugs are used for procedural sedation and analgesia (PSA) in Emergency Departments, including propofol, ketamine, benzodiazepines, narcotics, barbiturates, and others, but propofol has gained popularity despite its potential to cause cardiac and respiratory depression. Obviously the optimal agent or combination of agents has not been identified. There are reasons to believe that a combination of ketamine and propofol may have advantages over other agents/combinations. These include better hemodynamic stability at equal depth of anesthesia with a combination of ketamine/propofol than with propofol alone, less respiratory depression with the combination in comparison to propofol alone, and preservation of respiratory drive with the combination. There is one study of ketamine/propofol in Emergency Department (ED) procedural sedation which demonstrated the safety and effectiveness of the combination, but did not compare it to any other agents or combinations. The investigators designed a randomized, placebo controlled study to compare propofol to propofol and ketamine for adequacy of sedation and respiratory depression in Emergency Department procedural sedation and analgesia. The investigators hypothesis was that the combination of propofol/ketamine would produce better sedation and/or less respiratory depression than propofol alone.

Read more

Methods

Study design

The investigators conducted a randomized, prospective, double-blinded study of all patients receiving procedural sedation. From April 2007 until July 2009 in the ED of a 274 bed university teaching hospital. The study was approved by the University of Missouri's Institutional Review Board and informed consent was obtained from all participants.

Read the detailed description

Introduction

Numerous drugs and combinations of drugs are used for procedural sedation and analgesia (PSA) in Emergency Departments, including propofol, ketamine, benzodiazepines, narcotics, barbiturates, and others, but propofol has gained popularity despite its potential to cause cardiac and respiratory depression. Obviously the optimal agent or combination of agents has not been identified. There are reasons to believe that a combination of ketamine and propofol may have advantages over other agents/combinations. These include better hemodynamic stability at equal depth of anesthesia with a combination of ketamine/propofol than with propofol alone, less respiratory depression with the combination in comparison to propofol alone, and preservation of respiratory drive with the combination. There is one study of ketamine/propofol in Emergency Department (ED) procedural sedation which demonstrated the safety and effectiveness of the combination, but did not compare it to any other agents or combinations. We designed a randomized, placebo controlled study to compare propofol to propofol and ketamine for adequacy of sedation and respiratory depression in Emergency Department procedural sedation and analgesia. Our hypothesis was that the combination of propofol/ketamine would produce better sedation and/or less respiratory depression than propofol alone.

Methods

Study design

We conducted a randomized, prospective, double-blinded study of all patients receiving procedural sedation. From May 2007 until March 2009 in the ED of a 274 bed university teaching hospital. The study was approved by the University of Missouri's Institutional Review Board and informed consent was obtained from all participants.

Study setting and population

All patients requiring PSA in the ED were viewed as potential subjects unless they were pregnant, less than 1 year of age, history of prior adverse reaction to anesthesia, underlying cardiac or pulmonary disease, hepatic dysfunction, porphyria, psychiatric illness, allergy to eggs/soybeans, increased intracranial or intraocular pressure, abnormal airway pathology or an American Society of Anesthesiologists (ASA) score of 3 or greater. The attending ED physician would then approach the patient to enroll them in the study. If the patient accepted they were randomized by the hospital pharmacy.

Study protocol

An ED attending physician was dedicated to PSA throughout the procedure. Patients had EKG, blood pressure, respiratory rate, pulse oximetry, and end-tidal carbon dioxide (PetCO2) monitored, had IV access obtained and were placed on nasal cannula oxygen supplementation. All patients received pre-procedure analgesia with 0.5 to 1.5 mcg/Kg of fentanyl and all patients had reflective sunglasses placed so as to obscure eye movements from the staff.

Subjects were randomized by the pharmacy in blocks of ten. Consecutively numbered pre-filled 3cc syringes were prepared by the pharmacy staff once they received a signed and dated study enrollment sheet from the ER staff with the patients weight in kilograms provided. All physicians, nurses, patients and study personnel were blinded to the contents of the syringes which were hand delivered by pharmacy personnel.

Patients were randomized to receive either 0.5 mg/Kg of ketamine or placebo (normal saline) delivered to the emergency room sedating physician in a 3 cc syringe containing a clear/colorless solution. This solution was delivered intravenously over a one minute infusion. On completion of this infusion all patients received propofol starting at 1 mg/Kg over 2 minutes and supplemented with repeated boluses of 0.5 mg/Kg to maintain adequate sedation. Patients were felt to be adequately sedated once they received a Colorado Behavioral Numerical Pain Scale (CBNPS) score of 0 to 113(table 1.) Patients were monitored after the procedure until a normal level of consciousness was observed.

The quantity of all drugs delivered were recorded. During the procedure all patients were monitored for 5 respiratory depression markers:

  • PetCO2 rise of ³ 5 mm/Hg
  • Respiratory rate < 8 br/min
  • arterial oxygen saturation (SaO2) < 90%
  • Apnea ³ 15 seconds
  • Airway manipulation

Physicians were permitted to intervene and provide any supportive/resuscitative measures at there discretion despite the pre-specified respiratory depression markers.

All data were collected and recorded on standardized Hospital PSA forms. Data was collected for the entire time frame of the individual procedural sedations. Following the completion of the procedural sedation a second form was filled out by both the sedating physician and monitoring nurse recording specifically any respiratory events/rescue interventions and overall satisfaction with the procedural sedation. The overall quality of the PSA was evaluated by the physician/nurse performing the sedation as one of the following:

  1. Not satisfied
  2. Somewhat satisfied
  3. Satisfied
  4. Very satisfied
  5. Excellent

All data was recorded on a secure computer in spreadsheet form (Microsoft Excel 2003, Microsoft Corporation, Redmond, WA) for later analysis.

Outcome Measures

Four endpoints were defined prior to study initiation:

Respiratory Depression. A difference in evidence of respiratory depression between the groups. Respiratory depression was defined as the occurrence of any of the 5 markers.

Satisfaction with PSA. A difference in the evaluation of the quality of the sedation by the providers.

Quality of PSA. Number of patients with a CBNPS of 0.

Propofol usage. Did the addition of ketamine significantly reduce the amount of propofol needed to produce adequate PSA.

Data analysis We plan to enroll 100 patients in each group. This is based on an estimate of a 40% incidence of respiratory depression with propofol alone, a reduction to 20% with the combination of ketamine/propofol, an a of 0.05 and a power of 0.8.14-16. An interim analysis was conducted at enrollment of 100 patients using a significance of 0.025 for difference in respiratory depression.

Respiratory depression and CBNPS were compared using a chi-squared test and Satisfaction with PSA and Quality of PSA were compared using a t-test. Tests were done with Primer of Biostatistics (Version 6.0, Stanton A. Glantz, 2005).

Being tested
Ketamine, Placebo, Fentanyl, Propofol
Medical subject headings
Agnosia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • KetamineDrug

    Also called Ketalar

    Ketamine was given as a 0.5mg / Kg bolus.

  • PlaceboDrug

    Placebo given as an bolus to control group.

  • FentanylDrug

    Also called Sublimaze

    Fentanyl 0.5 - 1.5 micrograms given to both arms prior to Ketamine or placebo

  • PropofolDrug

    Also called Diprivan

    Propofol given to both arms to maintain sedation throughout procedure.

Study groups in NCT01126957
Study groupRoleWhat they receive
KetamineExperimentalParticipants received 0.5-1.5 micrograms/kg Fentanyl, followed 0.5 mg/kg Ketamine infusion, followed by propofol to maintain sedation.
Receives: Drug: Ketamine; Drug: Fentanyl; Drug: Propofol
PlaceboPlacebo comparatorParticipants received 0.5-1.5 micrograms/kg Fentanyl, followed by placebo infusion, followed by propofol to maintain sedation.
Receives: Drug: Placebo; Drug: Fentanyl; Drug: Propofol

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Respiratory Depression

    1. Endotracheal carbon dioxide (ETCO2) rise > 5mm/hg
    2. Arterial oxygen saturation (SaO2) <90%
    3. Respiratory rate (RR) < 8 br/min
    4. Apnea > 15 sec
    5. airway manipulation

    Measured: Baseline and throughout procedure

Secondary outcomes (1)
  1. Satisfaction With Procedural Sedation

    Score of 1 to 5 with 5 being completely satisfied and 1 being not satisfied at all was recorded by both the monitoring nurse and the physician performing the procedural sedation

    Measured: 20 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 May 2010 (estimated)
  2. Study startMay 2007
  3. Primary completionMar 2010
  4. Study completionMar 2010

Why it stopped: Investigator left institution.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
107 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01126957
Sponsor's protocol ID
Project Number: 1084480
Status last verified
Mar 2023
First submitted
11 May 2010
Last updated
24 Apr 2023
Data monitoring committee
No
Individual data sharing
Undecided

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in